BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pasquale R, Giannotta JA, Barcellini W, Fattizzo B. Bortezomib in autoimmune hemolytic anemia and beyond. Ther Adv Hematol 2021;12:20406207211046428. [PMID: 34795889 DOI: 10.1177/20406207211046428] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang H, Lin K, Lin J, Lin Y, He H, Wang Y, Yu S, Chen J, Cheng T. Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review. Pharmaceuticals 2022;15:1377. [DOI: 10.3390/ph15111377] [Reference Citation Analysis]
2 Akgun Y. Bortezomib may be an effective treatment for myelin oligodendrocyte glycoprotein antibody-associated disease. Medical Hypotheses 2022;168:110972. [DOI: 10.1016/j.mehy.2022.110972] [Reference Citation Analysis]
3 Pattanakitsakul P, Sirachainan N, Tassaneetrithep B, Priengprom T, Kijporka P, Apiwattanakul N. Enterovirus 71-Induced Autoimmune Hemolytic Anemia in a Boy. Clin Med Insights Case Rep 2022;15:11795476221132283. [PMID: 36277905 DOI: 10.1177/11795476221132283] [Reference Citation Analysis]
4 Fattizzo B, Barcellini W. New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia. Transfus Med Rev 2022:S0887-7963(22)00039-6. [PMID: 36182620 DOI: 10.1016/j.tmrv.2022.08.001] [Reference Citation Analysis]
5 Chen M, Shortt J. Plasma-cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP). Transfusion Medicine Reviews 2022. [DOI: 10.1016/j.tmrv.2022.09.001] [Reference Citation Analysis]
6 Pacillo L, Giardino G, Amodio D, Giancotta C, Rivalta B, Rotulo GA, Manno EC, Cifaldi C, Palumbo G, Pignata C, Palma P, Rossi P, Finocchi A, Cancrini C. Targeted treatment of autoimmune cytopenias in primary immunodeficiencies. Front Immunol 2022;13:911385. [DOI: 10.3389/fimmu.2022.911385] [Reference Citation Analysis]
7 Fattizzo B, Barcellini W. Autoimmune hemolytic anemia: causes and consequences. Expert Rev Clin Immunol 2022;:1-15. [PMID: 35702053 DOI: 10.1080/1744666X.2022.2089115] [Reference Citation Analysis]
8 Trewin BP, Freeman I, Ramanathan S, Irani SR. Immunotherapy in autoimmune encephalitis. Curr Opin Neurol 2022;35:399-414. [PMID: 35674084 DOI: 10.1097/WCO.0000000000001048] [Reference Citation Analysis]
9 Xiao Z, Murakhovskaya I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics 2022;14:1035. [DOI: 10.3390/pharmaceutics14051035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Crawford LR, Neparidze N. Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Michel M. Adult Evans' Syndrome. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.12.004] [Reference Citation Analysis]